Obesity Is a Medical Condition and Not a Personal Fault: New Research Report

November 3, 2020

Obesity is a major problem in the United States and Americans are beginning to understand that obesity is a medical condition, not a personal fault according to new research.

At ObesityWeek 2020 new research emerges. For this research, Ted Kyle, RPH, MBA, and a team of obesity experts surveyed a total of 7,076 adults in 2017 and 2020. They found that significantly more respondents – 42% – agreed in 2020 that people with obesity need less blame and more medical help. Only 26% disagreed. Just three short years ago, only 30% of Americans agreed with this idea and 39% disagreed.

On top of that, Kyle and his colleagues saw a big shift in attitudes about hiring people with obesity. Two-thirds of respondents in 2020 said they would interview a person with obesity for a job. In 2017, that number was significantly smaller, only 57%.

Kyle said that this is good news, “Obesity is a biological condition that is mostly inherited. A person’s genes set the table for obesity, and the environment where we all live serves it up. If a person is biologically resistant, they are unlikely to gain weight in an environment that promotes obesity. But a susceptible person will. So it makes sense to deal with this condition like any other medical condition. Find effective ways to prevent it and provide people who already have it with effective medical care to reduce the impact on health.”

Joe Nadglowski, President and CEO of the Obesity Action Coalition, was one of the co-authors of this study. He linked these findings back to the decision in 2013 by the American Medical Association to recognize that obesity is a complex, chronic disease. “Before 2013, just about everyone’s assumption was that obesity was a problem of bad choices and unhealthy behavior. But now, people are coming to realize it is more complicated than that. Simply blaming people is counterproductive. It leads to worse, not better, health. So, we’re glad to see progress toward better public understanding of obesity,” said Nadglowski.

To view the full presentation on this research visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”